Zelthy Advanced Therapies is a purpose-built orchestration platform for advanced therapy medicinal products (ATMPs), including CAR-T cell therapies, gene therapies, and other personalised medicine programs. It manages the complete chain of custody from a patient's apheresis collection through manufacturing, quality control release, logistics, and final infusion — ensuring chain of identity and chain of condition at every handoff. Unlike general-purpose supply chain tools, the platform is designed around the patient-specific nature of ATMPs, where each manufactured batch is tied to a single patient and time windows between steps are measured in hours rather than days. Key features and functionalities The platform provides four AI agents covering the end-to-end ATMP workflow: - a Chain-of-Custody Orchestration Agent that tracks identity and condition at every handoff and flags deviations before the therapy window closes; - a Logistics and Scheduling Agent that optimises apheresis, manufacturing, and infusion appointments across sites to minimise patient wait time; - a Cold Chain Monitoring Agent that processes real-time IoT temperature data and predicts time-to-excursion before a breach occurs; - and an Outcome Tracking Agent that structures long-term patient outcome data required for FDA and EMA post-approval reporting. Additional capabilities include site and hospital coordination across apheresis centres, CDMOs, and treatment sites; GxP-compliant audit trails with full 21 CFR Part 11 compliance; and CDMO and hospital information system integrations. The platform is designed to scale from clinical trials through to commercial launch without re-implementation. Primary value and solution provided Advanced therapy programs fail operationally before they fail clinically — delays at a single logistics handoff, a missed temperature excursion, or a scheduling conflict between an apheresis centre and a CDMO can mean the loss of a patient's only treatment opportunity. Zelthy Advanced Therapies eliminates these failure modes by replacing the manual coordination spreadsheets and fragmented systems that most emerging advanced therapy companies rely on with a single AI-orchestrated platform. It gives therapy operations teams real-time visibility and automated intervention across the 15–20 organisations involved in a typical CAR-T workflow, and ensures every regulatory obligation — from chain-of-identity documentation to long-term outcome reporting, is met without manual effort.